Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma
17 December 2020
Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma
Leading international law firm Clifford Chance has advised ICG Strategic Equity, as the lead investor, in CapVest’s GP-led secondary in respect of Curium Pharma, one of the largest single-asset secondary transactions to take place in 2020.
Dual-headquartered in Paris and London, with manufacturing facilities across Europe and the United States, Curium Pharma is a global vertically integrated developer, manufacturer and distributer of medical radioisotopes and radiopharmaceuticals for use in diagnostic imaging and therapeutic procedures. It was reportedly the subject of a highly contested sale process earlier in this year, before London-based sponsor CapVest decided to explore a secondary process after the onset of the global pandemic.
good morning, everyone. welcome to today on a saturday morning. i m lester holt. boo. and i m amy robach. didn t work. we felt at moments maybe we weren t alone in that prison. it was dark, it was creepy. i heard things. it was one of those what were we thinking things going into this darkened prison. we weren t alone. we were there with the folks from sci-fi s ghost hunter s program. they brought their van, their gear. we supplied plenty of the fear. and we re going to show you what happened. there were some things that kind of made you a little uneasy. yeah. like you said, maybe we re sleeping with the lights on now at least for a couple of nights. coming up later in the broadcast, the case against dr. conrad murray. closing arguments are expected next week. and the defense is trying to show mooix michael jackson s death may have been caused by prescription drugs he was already taken. friday s testimony brought us more fireworks from the witness stand. then an u